Skip to content

Released Mar 13, 2020, after the close

10-K filed Mar 16, 2020, 76 days after period end · 0001564590-20-010890

Q4 2019 · 10-K
Revenue$11.31M−40.8% vs Q4 2018−7.9% vs Q3 2019
Net Income-$14.79MN/M vs Q4 2018N/M vs Q3 2019
EPS Diluted-$0.65N/M vs Q4 2018N/M vs Q3 2019
Operating Incomederived-$14,782,000N/M
Operating Cash Flowderived-$13,156,000N/M
Margins · derived
Operating margin-130.8%−113.6 pt vs Q4 2018
Net margin-130.8%−123.0 pt vs Q4 2018

What the release said

The release

Same quarter

MetricQ4 2019Q4 2018Q4 2017
Revenue$11.31M$19.09M$4.04M
Net Income-$14.79M-$1.49M-$15.34M
EPS Diluted-$0.65-$0.07-$33.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR